Loading
A phase 3 trial of PSMA-1007 F-18 run by ABX advanced biochemical compounds GmbH in prostate cancer, now recruiting.
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06122584 by ABX advanced biochemical compounds GmbH, with 380 participants planned, started 2024-06-13. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/